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Abstract
Background: Antimicrobial peptides (AMPs) protect the host intestinal mucosa against microorganisms. Abnormal
expression of defensins was shown in inflammatory bowel disease (IBD), but it is not clear whether this is a primary defect.
We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD.
Methodology/Principal Findings: Mucosal gene expression of 81 AMPs was assessed in 61 IBD patients before and 4–6
weeks after their first infliximab infusion and in 12 control patients, using Affymetrix arrays. Quantitative real-time reverse-
transcription PCR and immunohistochemistry were used to confirm microarray data. The dysregulation of many AMPs in
colonic IBD in comparison with control colons was widely restored by infliximab therapy, and only DEFB1 expression
remained significantly decreased after therapy in the colonic mucosa of IBD responders to infliximab. In ileal Crohn’s disease
(CD), expression of two neuropeptides with antimicrobial activity, PYY and CHGB, was significantly decreased before therapy
compared to control ileums, and ileal PYY expression remained significantly decreased after therapy in CD responders.
Expression of the downregulated AMPs before and after treatment (DEFB1 and PYY) correlated with villin 1 expression, a gut
epithelial cell marker, indicating that the decrease is a consequence of epithelial damage.
Conclusions/Significance: Our study shows that the dysregulation of AMPs in IBD mucosa is the consequence of
inflammation, but may be responsible for perpetuation of inflammation due to ineffective clearance of microorganisms.
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Introduction
Inflammatory bowel diseases (IBDs), Crohn’s disease (CD) and
ulcerative colitis (UC), are multifactorial diseases of unknown
etiology, characterized by chronic relapsing inflammation of the
gastro-intestinal tract. Immune, genetic and environmental factors
are thought to contribute to IBD [1].
Many findings suggest that the intestinal flora plays an important
roleinthepathogenesisofIBD.First,severalknockoutanimalmodels
of IBD in a germ-free environment fail to develop intestinal
inflammation [2–6]. Second, recurrence of CD in the neoterminal
ileum after ileal resection with ileocolonic anatomosis has been shown
to be dependent on faecal stream [7]. Third, luminal contents trigger
inflammation [8], and T-cell responses in CD patients are directed
against the autologous bacterial flora [9]. Fourth, in CD mucosa
adherent Escherichia coli has been found [10]. Finally, antibiotics and
probiotics do often ameliorate the symptoms in IBD [11].
Together these points support the microbial contribution to IBD,
indicating that a basic antimicrobial mucosalbarrier defectcould be
responsible for susceptibility to this disease. The gastro-intestinal
tract is constantly exposed to a wide range of microorganisms. In
ordertomaintainthemucosalbarrierintegrityagainsttheseluminal
microorganisms, the intestinal epithelial cells produce a variety of
antimicrobial peptides (AMPs), like defensins, lysozyme and
cathelicidins. AMPs contribute to innate immunity and can be
considered as natural peptide antibiotics. Several recent studies
indicate that an abnormal expression of AMPs may exist in IBD
[12]. Patientswith Crohn’s ileitis (CDi) show a reduced antibacterial
activity in their intestinal mucosal extracts and display a decreased
expression of the Paneth cell alpha-defensins (DEFA5 and DEFA6)
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independent of the degree of inflammation and associated with
NOD2 mutations. However, another study found no correlation
between the decreased alpha-defensins expression and the NOD2
status but linked the decrease to inflammation [15]. A study by
Noble et al. [16] showed a regional variation of DEFA5 and DEFA6
gene expression in non-inflamed intestinal biopsies of normal
subjectsandUCpatients,withhigh expression intheterminalileum
andexpression decreasingasthe biopsylocation becamemore distal
in the colon. They further found a marked upregulation of DEFA5
and DEFA6 expression in inflamed UC colon. As compared to UC,
Crohn’s colitis (CDc) is characterized by a decreased antimicrobial
activity in cationic protein extracts from colonic biopsies and an
attenuated induction of beta-defensins (DEFB4/HBD-2, DEFB103),
cathelicidin LL37, and antimicrobial antiproteases elafin and SLPI
[17–21]. The defective mRNA induction of beta-defensins in CDc
may be partly due to low DEFB4 gene copy number [22]. However,
no association with DEFB4 gene copy number was found on
DEFB4 protein level [23].The DEFB1 expression was found to be
decreased in both active UC and CD [18].
It can be argued, however, that the abnormal AMP status of IBD
patients is the consequence of an altered interaction betweenbarrier
and microflora interaction rather than a causative factor for
disturbed microbial clearance. The hypothesis for the present study
was that disturbed AMP expression in IBD is a pathogenic factor.
When true, the prediction is that after pharmacological suppression
of inflammation the underlyingdefective expression of AMPs would
be unmasked. However, if the alternative hypothesis is true, namely
that abnormalities in AMP production are a secondary phenom-
enon, it can be predicted that after disappearance of inflammation
the AMP expression in IBD normalizes. To distinguish between
these two hypotheses, we investigated the intestinal mucosal gene
expression of AMPs in active IBD patients and the impact of anti-
inflammatory therapy with infliximab (Remicade; Centocor, Inc.,
Malvern, PA, USA), a chimeric antibody against tumor necrosis
factor-alpha (TNF-alpha), on the mucosal gene expression of AMPs
in IBD patients, using microarray technology.
Methods
Ethics statement
The study was carried out at the University Hospital of Gasthuisberg
in Leuven (ClinicalTrials.gov number, NCT00639821). The ethics
committee of the University Hospital approved the study and all
individuals gave written informed consent.
Antimicrobial peptides
The name AMPs is somewhat confusing and large number of
very diverse proteins has been given this name in the literature.
There are the ‘‘classic’’ AMPs that were discovered for their action
to kill microorganisms (e.g. defensins and cathelicidins), and other
proteins that were discovered for other biological functions but
they were reported to exert antimicrobial activities (e.g. neuro-
peptides, chemokines and proteinase inhibitors) [24].
The PubMed database was searched using the keywords
‘‘antimicrobial peptide’’ and ‘‘antimicrobial protein’’, and 81
peptides/proteins with reported antimicrobial activity were
selected and analysed in this study (Table S1). We excluded the
AMPs that were identified as chemokines [25] because of their key
role in the inflammatory response in IBD.
Patients and biopsy specimens
Sixty-one patients with active IBD (24 UC, 19 CDc and 18
CDi), refractory to corticosteroids and/or immunosuppression,
and a control group of 12 individuals (6 colon and 6 ileum) who
underwent endoscopy for screening for polyps were studied. The
patients underwent endoscopy with biopsies from diseased bowel
(colon for UC and CDc, and ileum for CDi) within a week prior to
the first intravenous infusion of 5 mg infliximab per kg body
weight. They underwent a second endoscopy with biopsies 4 weeks
after the first infliximab infusion in case of a single infusion and at
6 weeks if they received a loading dose of infliximab at weeks 0, 2
and 6. The biopsies were taken at sites of active inflammation but
at a distance of ulcerations. In the case of healing at control
endoscopy, the biopsies were obtained in the areas where lesions
were present before therapy. The endoscopist was not blinded to
treatment. Half of the biopsies were immediately snap-frozen in
liquid nitrogen and stored at 280uC until RNA isolation and/or
immunohistochemistry, except for the biopsies from 1 CDc patient
after infliximab treatment which were of poor technical quality.
The residual biopsies were fixed in Carnoy’s fixative for up to
5 hours and then dehydrated, cleared and paraffin-embedded for
histologic examination. The features of chronic intestinal inflam-
mation were scored in haematoxylin-eosin stained slides from the
paraffin blocks of each patient using a previously reported scoring
system for UC [26] and for CD [8]. The pathologists who scored
the biopsies (KG and GDH) were blinded to treatment.
The response to infliximab was assessed 4 to 6 weeks after the
first infliximab treatment. For UC and CDc, the response to
infliximab was defined as a complete mucosal healing with a
decrease of at least 3 points on the histological score for CDc [8]
and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a
decrease to grade 0 or 1 on the histological score for UC [26,27].
Patients who did not achieve this healing were considered non-
responders although some of them presented endoscopic and/or
histologic improvement. Of the 43 colonic IBD (IBDc) patients, we
identified 20 responders (8 UC and 12 CDc) and 23 non-
responders (16 UC and 7 CDc). If the same response criteria of
CDc were used for CDi, only one patient showed complete
endoscopic and histologic healing. Therefore, we had to use less
strict response criteria for CDi. Patients with a clear improvement
of the ulcerations and a decrease on the histological score [8] were
considered responders. Of the 18 CDi patients, we identified 8
(partial) responders and 10 non-responders.
The baseline characteristics of the patients are summarized in
table 1.
RNA isolation and oligonucleotide array hybridization
Total RNA was extracted from the biopsy specimens using the
RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the
manufacturer’s instructions. The integrity and quantity of total
RNA were assessed with a 2100 Bioanalyzer (Agilent, Waldbronn,
Germany) and Nanodrop ND-1000 spectrophotometer (Nano-
drop technologies). As previously described [28], total RNA was
analyzed with the Affymetrix Human Genome U133 Plus 2.0
Arrays (Affymetrix, Santa Clara, CA, USA), which comprised of
54675 probe sets covering the whole genome. The microarray
data were deposited at Gene Expression Omnibus under the series
accession number GSE16879, and the microarray data were
handled in accordance with the MIAME (Minimum Information
About a Microarray Experiment) guidelines.
Microarray data analysis
A glossary of terms used in the analysis is provided in Appendix
S1.
The Affymetrix raw data (.cel files) were analyzed using
Bioconductor tools [29] in R (version 2.7.2, http://www.
r-project.org/). The robust multichip average method [30] was
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expression value for each probe set. Probe set annotations were
obtained through the Affymetrix NetAffx website (http://www.
affymetrix.com/analysis/index.affx) or the UCSC Genome
Browser website (http://genome.ucsc.edu/) or the NCBI website
(http://www.ncbi.nlm.nih.gov/). For comparative analysis, linear
models for microarray data (LIMMA) [31] was performed for all
the probe sets (54675 probe sets) present on the microarray to
identify probe sets that are different between the groups, based on
moderated t-statistics. To correct for multiple testing, the false
discovery rate (FDR) was estimated from p-values derived from the
moderated t-statistics using the method of Benjamini and
Hochberg [32]. Probe sets with a.2-fold change (FC) and a
FDR,0.05 were considered biologically significant. In this study,
we focused on the microarray data of AMP genes. We selected the
results from all performed comparative analyses for the probe sets
encoding AMP genes, interleukin 8 (IL8) gene (probe set
202859_x_at) and villin 1 (VIL1) gene (probe set 205506_at)
(Table S2).
Quantitative real-time reverse-transcription PCR (qPCR)
To validate the microarray data, qPCR was performed for
DEFA5, DEFA6, DEFB4, DEFB1, liver expressed antimicrobial
peptide 2 (LEAP2) and peptide YY (PYY). Beta-actin was used as
the endogenous reference gene. Total RNA from the same
samples as for microarray analysis was used. cDNA was
synthesized from 0.5 mg of total RNA using the RevertAid H
Minus First Strand cDNA synthesis kit (Fermentas, St. Leon-Rot,
Germany), following the manufacturer’s protocol. Primers and
dual-labeled probes were designed using OligoAnalyzer 3.0
software (http://biotools.idtdna.com/analyzer/) and synthesized
by Sigma-Genosys (Haverhill, UK). The oligonucleotide sequences
are available upon request. Multiplex real-time PCR was
performed in a final reaction volume of 25 ml on a Rotor-Gene
3000 instrument (Corbett Research, Mortlake, Australia), using
QuantiTect Multiplex PCR NoROX Kit (Qiagen, Venlo, NL),
according to the manufacturer’s instructions. Cycle threshold
values were determined by Rotor-Gene 6.0.16 software. All
samples were amplified in duplicate reactions. The relative
expression of target mRNA levels were calculated as a ratio
relative to the beta-actin reference mRNA [33]. Results were
analyzed using the Mann-Whitney U-test for unpaired samples
and Wilcoxon signed-rank test for paired samples using SPSS 16.0
software (SPSS, Chicago, IL). A p-value of ,0.05 was considered
significant.
Immunohistochemistry
To determine the protein localization of lysozyme (LYZ),
DEFA5 and DEFB1, immunohistochemical staining was per-
formed on 5 mm-thick cryostat sections from fresh-frozen intestinal
mucosal biopsies obtained during endoscopy from the IBD
patients and the control individuals. All procedures were
conducted at room temperature. Briefly, cryostat sections were
air-dried overnight after they were cut, fixed in acetone for 10 min
and rinsed in phosphate-buffered saline (PBS) for 5 min. Sections
were pre-treated with Dual Endogenous Enzyme-Block Reagent
(Dako Belgium nv/sa, Heverlee, Belgium) for 10 min, washed in
PBS and incubated for 30 min with the primary antibody (Ab)
against LYZ (rabbit polyclonal anti-human lysozyme Ab, EC
3.2.1.17, code A 0099, from Dako, dilution 1:1500), DEFA5
(mouse monoclonal anti-human alpha defensin NP5 Ab, clone nr
8C8, code ab62757, from Abcam plc, Cambridge, UK, dilution
1:250) and DEFB1 (rabbit polyclonal anti-human beta defensin 1,
kindly provided by Dr. Tomas Ganz, UCLA, Los Angeles, USA,
dilution 1:200). After two times 5 min of washing with PBS, the
sections were incubated for 30 min with the secondary antibody,
PowerVision Poly-HRP-anti-mouse/rabbit/rat IgG (Klinipath
BVBA, Olen, Belgium), followed by 2 times 5 min washing with
Table 1. Baseline characteristics of the UC, CDc and CDi patients.
Characteristics UC (n=24) CDc (n=19) CDi (n=18)
Male/Female (%) 14/10 (58.3/41.7) 11/8 (57.9/42.1) 9/9 (50/50)
Median (IQR) age at first IFX (years) 41.4 (31.9–50.9) 31.8 (23.7–47.5) 46.4 (34–55.3)
Median (IQR) weight at first IFX (kg) 72.5 (67–80.3) 68 (60.5–77.5) 63.5 (56.1–79.5)
Median (IQR) duration of disease prior to first IFX (years) 7.3 (2.7–17.1) 6.4 (3.1–20.9) 22.3 (11.1–28)
Extent of disease
UC Left-sided colitis (%) 7 (29.2) NA NA
Pancolitis (%) 17 (70.8) NA NA
CD Ileocolon (%) NA 5 (26.3) 9 (50)
Ileum (%) NA 0 (0) 9 (50)
Colon (%) NA 14 (73.7) 0 (0)
Median (IQR) C-reactive protein at first IFX (mg/dL) 4 (1.8–19.1) 10.2 (4.3–35) 7.4 (2.3–10.9)
Concomitant medication at first IFX (%)
5-Aminosalicylates 18 (75) 8 (42.1) 5 (27.8)
Corticosteroids 7 (29.2) 4 (21.1) 2 (11.1)
Azathioprine/6-Mercaptopurine 15 (62.5) 14 (73.7) 7 (38.9)
Methotrexate 0 (0) 0 (0) 0 (0)
Corticosteroids+Immunosuppressants 3 (12.5) 2 (10.5) 1 (6)
Active smoking at first IFX (%) 2 (8.3) 6 (31.6) 6 (33.3)
IQR, interquartile range; IFX, infliximab; NA, not applicable.
doi:10.1371/journal.pone.0007984.t001
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10 min. After color development, the sections were rinsed in
distilled water and were counterstained with Mayer’s haematox-
ylin for 1 min. After washing with distilled water, the sections were
mounted in glycerol medium (BDH, Dorset, UK). As negative
controls, cryostat sections were processed as described, however
without addition of the primary antibody. The stains were
evaluated by two pathologists (KG and GDH) and the location
of the staining product in the tissues was noted.
Results
AMP expression in intestinal mucosa from IBD patients
before and after first infliximab treatment
Pairwise comparisons were performed for intestinal mucosal
mRNA expression of 81 AMP genes between controls and patients
before and after infliximab treatment in UC, CDc, IBDc (UC and
CDc) and CDi, using LIMMA. The results (FC, p-value and FDR)
of the performed comparative analyses for all the probe sets
encoding AMP genes are given in Table S2. Figure 1A–F shows
the individual microarray expression values for DEFB1, LEAP2,
PYY, DEFA5, DEFA6 and DEFB4, respectively.
Colonic expression. First, we investigated whether there
were differences in gene expression of AMPs in UC compared
with CDc. Although no differences in expression of AMP genes at
baseline reached significance comparing UC and CDc, we noted,
however, that DEFB4 mRNA expression was non-significantly
increased in UC at baseline as compared with CDc at baseline
(FC=3.08, FDR=0.18) (Table S2).
Next, we studied the AMP gene expression in inflamed colonic
mucosa of IBD patients and the effect of infliximab treatment on
the AMP gene expression. Table 2 shows the FC of the probe sets
encoding AMP genes that were significant in one of the performed
comparative analyses in UC, CDc and IBDc.
DEFB1 and LEAP2 were the only AMP genes that showed a
more than 2-fold and significantly reduction in mRNA expression
in inflamed colon for both UC and CDc patients before infliximab
treatment as compared to control colons. Moreover, DEFB1
mRNA expression remained significantly more than 2-fold lower
in IBDc responders after infliximab treatment compared to control
colons (Table 2). A number of AMP genes (PYY, NTS, NPY, KNG1,
CST3, HIST1H2AB/HIST1H2AE and GRN) showed a more than
1.5-fold decreased expression in active IBDc before infliximab
treatment as compared with control colons, but they were not
Figure 1. Individual microarray log2 expression values for selected AMP genes in intestinal mucosa of IBD patients before and after
infliximab treatment and controls. (A) DEFB1 (probe set 210397_at), (B) LEAP2 (probe set 1552362_a_at), (C) PYY (probe set 207080_s_at), (D)
DEFA5 (probe set 207529_at), (E) DEFA6 (probe set 207814_at) and (F) DEFB4 (probe set 207356_at). Lines between 2 points represent the change in
expression before and after treatment for one patient. R: responders.
doi:10.1371/journal.pone.0007984.g001
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The expression of LEAP2, NTS, and HIST1H2AB/HIST1H2AE
remained more than 1.5-fold non-significantly lower after therapy
in IBDc responders compared to control colons (Table S2).
In contrast, the mRNA expression of 21 AMP genes (DEFA5,
DEFA6, DEFB4, LYZ, PI3, S100A7, S100A8, S100A9, S100A12,
PF4, PPBP, CSTA, ADM, C1R, C1QA, PLA2G2A, LTF, LCN2,
REG3A, NOS2A and ZC3HAV1) was more than 2-fold significantly
increased before treatment in active IBDc as compared with control
colons. Most of the AMP genes upregulated at baseline in active
IBDc decreased significantly more than 2-fold after infliximab
treatment in IBDc responders when compared to their baseline
samples. However, expression levels of DEFA5, LYZ and PLA2G2A
mRNA remained more than 2-fold significantly higher in the IBDc
responders after treatment compared to control colons (Table 2).
In non-responders to infliximab, no significant changes in AMP
genes were found after infliximab treatment as compared with
their baseline samples in UC, CDc and IBDc (Table S2). As
compared with control colons, the AMP genes that were
dysregulated at baseline remained dysregulated after treatment
in non-responders (Table 2).
Ileal expression. Table 3 shows the FC of the probe sets
encoding AMP genes that were significant in one of the performed
comparative analyses with CDi.
First, we studied the differential expression between CDi and
CDc at baseline. At baseline, the mRNA expression levels of
DEFA5, DEFA6, LEAP2, NTS, C5, HBA1/HBA2, REG3A and
REG3G were more than 2-fold significantly upregulated in CDi as
compared with CDc. The expression levels of SLPI, PI3, S100A7,
PYY and ADM were more than 2-fold significantly downregulated
at baseline in CDi as compared with CDc (Table 3).
Next, we investigated the effect of infliximab on AMP gene
expression in inflamed ileal mucosa of CDi patients.
Only two AMP genes (PYY and CHGB) both belonging to the
neuropeptide group showed a more than 2-fold significantly
decreased expression in active CDi at baseline when compared to
control ileums, and PYY expression remained more than 2-fold
significantly lower in CDi responders after infliximab treatment
compared to control ileums (Table 3). Other AMP genes that
showed a more than 1.5-fold non-significantly decreased expres-
sion in active CDi at baseline as compared with control ileums
were DEFA5, DEFA6, DEFB1, LEAP2, NPY, NTS, CHGA, KNG1,
Table 2. Fold change of the probe sets encoding AMP genes that were significant (.2-fold change and FDR,0.05, underlined) in
one of the performed comparative analyses in UC, CDc and IBDc.
before T vs control colons R after T vs control colons NR after T vs control colons R after T vs R before T
Probe Set ID Gene Symbol UC CDc IBDc UC CDc IBDc UC CDc IBDc UC CDc IBDc
205033_s_at DEFA1–A3 1.60* 1.51 1.56* 0.97 0.96 0.96 1.34 2.39* 1.60 0.76 0.78 0.77*
207529_at DEFA5 19.17* 64.58* 32.79* 47.12* 19.18 28.00* 18.45* 134.90* 33.81* 1.60 0.35 0.66
207814_at DEFA6 6.42* 16.91* 9.85* 8.71 6.34 7.25 6.16* 29.53* 9.92* 1.03 0.41 0.60
210397_at DEFB1 0.15* 0.21* 0.17* 0.29 0.39 0.35* 0.15* 0.16* 0.16* 1.61 1.34 1.45*
207356_at DEFB4 17.29* 5.61* 10.52* 1.12 1.37 1.26 6.76* 4.28 5.88* 0.08* 0.34 0.19*
1555745_a_at LYZ 17.57* 18.12* 17.81* 4.57 2.70 3.37 12.73* 28.02* 16.19* 0.24* 0.26* 0.25*
213975_s_at LYZ 7.27* 7.45* 7.35* 3.59 2.97 3.22* 7.19* 8.17* 7.47* 0.48* 0.50* 0.49*
1552362_a_at LEAP2 0.34* 0.38* 0.36* 0.55 0.56 0.56 0.32* 0.38* 0.34* 1.54* 1.39 1.45*
41469_at PI3 11.73* 7.74* 9.76* 2.98 2.47 2.67 7.75* 7.55* 7.69* 0.23* 0.33* 0.29*
203691_at PI3 11.03* 7.09* 9.08* 2.57 2.13 2.30 7.05* 6.89* 7.00* 0.19* 0.31* 0.26*
204971_at CSTA 5.73* 5.29* 5.53* 1.31 1.78 1.57 3.64* 7.17* 4.48* 0.39* 0.54 0.47*
205916_at S100A7 3.93* 2.29 3.09* 1.03 1.38 1.22 3.07 1.35 2.39 0.35* 0.63 0.49*
214370_at S100A8 3.54* 2.37* 2.96* 0.99 1.11 1.06 2.64* 4.73* 3.15* 0.47* 0.77 0.63*
202917_s_at S100A8 119.97* 65.89* 92.06* 1.65 2.26 1.98 39.87* 206.56* 65.78* 0.03* 0.08* 0.05*
203535_at S100A9 8.24* 4.84* 6.51* 0.83 1.11 0.98 4.79* 12.20* 6.36* 0.20* 0.45* 0.32*
205863_at S100A12 5.17* 3.35 4.27* 0.92 0.98 0.96 2.85 9.27* 4.08* 0.42 0.73 0.58*
202912_at ADM 4.19* 2.95* 3.59* 1.34 1.60 1.48 2.95* 3.33* 3.06* 0.34* 0.56 0.45*
206390_x_at PF4 4.04* 2.50* 3.26* 1.43 1.63 1.54 3.09* 2.52* 2.90* 0.33* 0.69 0.51*
214146_s_at PPBP 3.08* 1.96 2.52* 1.01 1.25 1.14 2.65 3.86* 2.97* 0.44* 0.92 0.67
212067_s_at C1R 4.72* 4.66* 4.69* 1.51 1.13 1.28 3.58* 6.56* 4.30* 0.51* 0.37* 0.43*
218232_at C1QA 3.23* 3.21* 3.22* 1.30 0.95 1.08 2.78* 3.92* 3.09* 0.49 0.34* 0.40*
203649_s_at PLA2G2A 4.64* 5.24* 4.89* 3.13 3.91 3.56* 4.51* 4.72* 4.57* 0.61 0.73 0.67*
202018_s_at LTF 4.50* 3.02* 3.77* 1.20 1.63 1.43 3.07 2.41 2.85 0.41* 0.68 0.55*
212531_at LCN2 17.66* 13.34* 15.60* 4.31 5.09 4.75 11.03* 13.18* 11.64* 0.21* 0.38 0.30*
205815_at REG3A 43.82* 60.29* 50.45* 8.12 12.13 10.25 22.93* 114.88* 37.45* 0.16 0.25 0.20*
210037_s_at NOS2A 7.86* 5.22* 6.56* 1.19 1.63 1.43 5.03* 4.07* 4.72* 0.15* 0.28* 0.22*
220104_at ZC3HAV1 2.39* 2.01* 2.22* 1.12 1.53 1.34 2.19* 2.63* 2.31* 0.53* 0.75 0.65*
*: FDR,0.05, underline: significant (.2-fold change and FDR,0.05), R: responders; NR: non-responders, T: treatment.
doi:10.1371/journal.pone.0007984.t002
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and also CHGB remained more than 1.5-fold non-significantly
lower after therapy in CDi responders than in control ileums,
except for DEFA5, DEFA6 and LEAP2 (Table S2).
Eight AMP genes (DEFB4, SLPI, PI3, S100A8, S100A9, ADM,
LCN2 and NOS2A) were more than 2-fold significantly upregulated
in CDi at baseline in comparison with control ileums. Only LCN2
mRNA expression remained more than 2-fold significantly
increased after infliximab treatment in CDi responders as
compared to control ileums (Table 3).
The relationship between AMPs and epithelial integrity,
inflammatory activity and Paneth cell mass
We also investigated the relationship between the mRNA
expression of AMPs that remained downregulated (DEFB1 in
IBDc and PYY in CDi) or upregulated (DEFA5, LYZ and
PLA2G2A in IBDc, and LCN2 in CDi) after therapy in responders
to infliximab and markers for epithelial integrity and for
inflammatory activity, respectively. The correlations were ana-
lyzed with the Spearman’s Rank Correlation test using the
microarray log2 mRNA expression values, and a p-value,0.05
was considered significant (Table 4). The ileum and colon
samples were analysed separately. The mRNA levels of the probe
set 205506_at representing VIL1, a marker of epithelial cell
content, correlated significantly with the mRNA levels of DEFB1
in the colon (Figure 2), and the correlation with PYY was
borderline significant (p-value=0.06) in the ileum. The mRNA
levels of the probe set 202859_x_at representing IL8,a n
inflammatory marker, were used to evaluate the correlation of
the mRNA levels of the upregulated AMPs with the inflammatory
activity. For the upregulated AMPs, the colonic mRNA levels of
DEFA5, LYZ and PLA2G2A showed a positive significant
correlation with the colonic mRNA levels of IL8, and there was
a positive significant correlation between the ileal mRNA levels of
LCN2 and IL8.
For DEFA5 and DEFA6, we observed a non-significantly
decreased expression in active CDi. In the ileum, PLA2G2A can
be used as a marker of Paneth cell mass. Therefore, we studied the
correlation of the microarray log2 expression levels in the ileum
between the alpha-defensins (DEFA5 and DEFA6) and PLA2G2A.
A positive significant relationship was identified between the
mRNA levels of the alpha-defensins and PLA2G2A in the ileum.
We found also a positive correlation between the mRNA levels of
the alpha-defensins and VIL1 in the ileum.
Table 3. Fold change of the probe sets encoding AMP genes that were significant (.2-fold change and FDR,0.05, underlined) in
one of the performed comparative analyses with CDi.
Probe Set ID Gene Symbol
CDi before T vs
CDc before T
CDi before T vs
control ileums
CDi R after T vs
control ileums
CDi NR after T vs
control ileums
207529_at DEFA5 6.60* 0.53 0.84 0.45
207814_at DEFA6 7.18* 0.53 0.86 0.42
207356_at DEFB4 0.71 4.61* 1.81 3.46
1552362_a_at LEAP2 13.38* 0.42 0.96 0.61
203021_at SLPI 0.18* 4.06* 2.22 3.46
41469_at PI3 0.12* 5.04* 1.72 2.98
203691_at PI3 0.11* 4.44* 1.17 2.47
205916_at S100A7 0.45* 0.96 0.86 0.96
202917_s_at S100A8 1.10 36.95* 2.41 34.58*
203535_at S100A9 0.92 5.36* 1.38 4.80
206291_at NTS 33.05* 0.13 0.40 0.13*
204260_at CHGB 1.08 0.44* 0.69 0.47
211253_x_at PYY 0.68* 0.37* 0.43* 0.35*
207080_s_at PYY 0.29* 0.10* 0.15* 0.05*
202912_at ADM 0.36* 3.30* 1.53 2.42
206390_x_at PF4 0.60* 1.82* 1.46 2.15*
205500_at C5 2.14* 1.73 1.66 1.66
204018_x_at HBA1/HBA2 2.74* 1.42 1.25 3.16
211699_x_at HBA1/HBA2 2.83* 1.42 1.26 3.18
217414_x_at HBA1/HBA2 2.76* 1.41 1.27 3.33
209458_x_at HBA1/HBA2 2.82* 1.37 1.22 3.07
214414_x_at HBA1/HBA2 2.94* 1.36 1.35 3.23
211745_x_at HBA1/HBA2 2.87* 1.40 1.25 3.18
212531_at LCN2 0.63* 22.20* 10.54* 16.22*
205815_at REG3A 7.85* 0.85 1.00 0.69
231661_at REG3G 2.34* 0.55 1.07 0.46
210037_s_at NOS2A 0.85 3.38* 3.02 2.74
*: FDR,0.05, underline: significant (.2-fold change and FDR,0.05), R: responders; NR: non-responders, T: treatment.
doi:10.1371/journal.pone.0007984.t003
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The differential mRNA expression of DEFB1, LEAP2, PYY,
DEFA5, DEFA6 and DEFB4, observed by microarray analysis, was
confirmed by qPCR (Figure S1, Table S3).
Moreover, using qPCR we found more genes that were
significantly different between the groups. However, it must be
noted that the statistical criteria used for defining significance by
qPCR (P-valueMann-Whitney test/Wilcoxon signed-rank test,0.05) were
less strict than the criteria used for microarray data significance by
LIMMA (.2-fold change and FDR,0.05). Also, fewer samples
were studied by qPCR than by microarray analysis.
Protein localization by immunohistochemistry
Immunohistochemistry was performed to determine where
DEFB1, DEFA5 and LYZ are expressed in the colonic and ileal
mucosa of healthy controls and IBD patients before and after
infliximab therapy.
In the normal intestine, DEFB1 was expressed in the epithelial
cell compartment, with accentuation at the surface of the biopsies
(Figure 3A–B). A similar expression pattern was seen in biopsies
from IBD patients, both before and after infliximab treatment. We
observed important epithelial cell loss in UC, CDc and CDi
biopsies before treatment, leading to an overall diminished DEFB1
expression in these samples (Figure 3C–D). This loss of protein
expression was only partly restored in responders after infliximab
therapy (Figure 3E–F).
DEFA5 was not expressed in the normal colonic mucosa,
whereas in the ileum it was mainly seen in the Paneth cells
(Figure 4A–B). Colonic biopsies from untreated IBD patients
frequently showed extensive epithelial defects and granulation
tissue with inflammatory cells, which stained positive for DEFA5
(Figure 4C). Epithelial cell loss was also observed in the ileum of
untreated CD patients. The overall diminished DEFA5 expression
in these biopsies was related to a decreased number of crypts
(Figure 4D). After successful infliximab therapy, there was some
regeneration of the epithelial cell compartment both in the colon
and ileum. DEFA5 expression in the IBD colon shifted partly from
inflammatory cells to rare metaplastic Paneth cells (Figure 4E).
There were no obvious differences in expression pattern of DEFA5
in ileal CD after therapy when compared with untreated CDi
patients (Figure 4D and F).
In healthy controls, LYZ was mainly expressed in Paneth cells
in the ileum and lamina propria mononuclear cells both in the
ileum and colon. Intestinal mucosal inflammation in untreated
IBD patients was characterized by an influx of numerous LYZ-
expressing polymorphonuclear leukocytes and histiocytes. After
successful infliximab therapy, the density of mucosal inflammatory
cells decreased, which resulted in a slightly diminished LYZ
expression (data not shown).
Discussion
The most commonly accepted hypothesis on the IBD etiology is
that abnormalities in the innate immune response by the mucosa
cause a loss of tolerance to commensal microbiota and alterations
in the composition of the gut microbiota. As a consequence for this
defect, the host immune system is overwhelmed by bacterial
antigens which lead to chronic immune-mediated intestinal injury.
There is evidence that expression and regulation of defensins, a
Table 4. Results (correlation coe ¨fficient and p-value) of the Spearman’s rank correlation analyses between the remaining
dysregulated AMPs after treatment in responders, VIL1 and IL8, and between alpha-defensins and PLA2G2A, using the microarray
log2 normalized expression values of the probe sets representing these genes.
Ileum samples (n=42) Colon samples (n=91)
Spearman’s rank correlation analyses correlation coe ¨fficient p-value correlation coe ¨fficient p-value
DEFB1 (210397_at) and VIL1 (205506_at) 0.332 0.032 0.708 ,0.001
PYY (207080_s_at) and VIL1 (205506_at) 0.289 0.064 0.409 ,0.001
DEFA5 (207529_at) and IL8 (202859_x_at) 20.416 0.006 0.22 0.036
PLA2G2A (203649_s_at) and IL8 (202859_x_at) 0.175 0.267 0.335 0.001
LYZ (213975_s_at) and IL8 (202859_x_at) 0.226 0.151 0.746 ,0.001
LCN2 (212531_at) and IL8 (211506_s_at) 0.477 0.001 0.477 ,0.001
DEFA5 (207529_at) and PLA2G2A (203649_s_at) 0.466 0.002 0.28 0.007
DEFA6 (207814_at) and PLA2G2A (203649_s_at) 0.565 ,0.001 0.31 0.003
DEFA5 (207529_at) and VIL1 (205506_at) 0.503 0.001 20.098 0.353
DEFA6 (207814_at) and VIL1 (205506_at) 0.43 0.004 20.125 0.237
doi:10.1371/journal.pone.0007984.t004
Figure 2. Scatterplot representing correlation between colonic
microarray log2 expression values of DEFB1 and VIL1. R:
responders; T: treatment.
doi:10.1371/journal.pone.0007984.g002
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mucosa are altered in IBD [12]. Whether the abnormalities in
defensins in the mucosa in IBD are primary defects or are the
consequence of inflammation is still debated. Moreover, other
AMPs may also play a role in the pathogenesis of chronic
inflammation. A large number of AMPs have been identified,
including the ‘‘classic’’ AMPs (e.g. defensins) and other molecules
that were first discovered for other biological activities (e.g.
neuropeptides) [34]. The main goal of the present study was to
investigate the influence of downregulation of inflammation by
infliximab, the IgG1 monoclonal antibody to TNF-alpha, on the
expression of AMPs in ileal and colonic CD and in UC in
comparison with normal controls, using microarray technology.
In this study we found no significant differences at baseline in
AMP expression in Crohn’s colitis mucosa in comparison with UC
mucosa using our strict predefined significance criteria. Our
microarray studies further showed that 21 AMPs were upregulated
in inflamed colon from IBD patients before infliximab treatment
in comparison with normal colons. For most of these upregulated
AMPs, colonic expression almost completely normalized after
treatment in IBD responders compared to their baseline samples.
Only the colonic expression of DEFA5, LYZ and PLA2G2A
remained significantly higher after treatment in IBD responders
compared to control colons. Increased expression of the former
AMPs is likely due to Paneth cell metaplasia which is readily found
in active colitis [12]. Noble et al. [16] also showed an increased
DEFA5 and DEFA6 expression in UC colon, and linked this to
Paneth cell metaplasia. Next, two AMPs were significantly
downregulated in active IBD colitis in comparison with normal
colons, namely LEAP2 and DEFB1. Expression of LEAP2 [35] in
IBD has not formerly been described. The LEAP2 colonic
expression increased non-significantly in IBD responders after
infliximab therapy but did not normalize completely. DEFB1
colonic expression remained significantly decreased in IBD
responders after infliximab therapy. The expression of a number
of AMP genes were dysregulated at baseline between ileal and
colonicCD.InactiveilealCrohn’sdiseasebeforetreatment8 AMPs
were upregulated versus control ileums, whereas DEFA5, DEFA6,
DEFB1 and LEAP2 were downregulated although not significantly.
Only PYY and CHGB were significantly downregulated in ileal CD
Figure 3. Immunohistochemical detection of DEFB1 protein in intestinal mucosa. Intense immunostaining of epithelial cells at the mucosal
surface in normal colon (A) and ileum (B). Severely reduced DEFB1 expression in UC (C) and CDi (D) before infliximab treatment. Partial restoration of
epithelial cell mass with DEFB1 staining in UC (E) and CDi (F) in responders to infliximab therapy (original magnification (OM): 650).
doi:10.1371/journal.pone.0007984.g003
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significantly lower after therapy in ileal CD responders. Quantita-
tive real-time reverse-transcription PCR and immunohistochemis-
try confirmed the microarray data.
In this study the close relationship between the remaining
downregulated AMPs after treatment (DEFB1 and PYY) with villin
1, a marker of epithelial cell mass, strongly suggests that the
decreased expression of these AMPs is the consequence of
epithelial cell and enterochromaffine cell damage and loss. It
was also shown with immunohistochemistry that although there is
epithelial layer restoration after treatment with infliximab in
responders, this restoration is incomplete and epithelial cell mass is
still decreased in comparison with normals. Similarly, in the ileum
the expression of alpha-defensins (DEFA5 and DEFA6) correlated
well with the expression of PLA2G2A, a marker for Paneth cells,
which suggests that Paneth cell loss is responsible for the non-
significantly decreased alpha-defensin expression in ileal CD. This
is in accordance with the data published by Simms et al. [15].
We also found no differences in expression of AMPs between
patients with CARD15 mutation(s) and patients without CARD15
mutation (data not shown) similar to the findings by Simms et al.
[15]. These authors found no significant relationship between the
alpha-defensin (DEFA5 and DEFA6) expression and CARD15
mutation in ileal Crohn’s disease. Because of the low number of
observations in our present study, we think further studies are
necessary.
Our study suggests that decreased expression of antimicrobial
peptides in IBD is not a primary defect causing the disease but a
consequence of epithelial cell loss in the ileum and colon, and loss
of Paneth cells in the ileum in an active phase of the disease. We
further hypothesize that decreased secretion of AMPs as a
consequence of epithelial damage in established IBD may
contribute to the perpetuation of inflammation because ongoing
bacterial invasion of the mucosa cannot be controlled, even despite
Paneth cell metaplasia resulting in an increased production of
some of the AMPs in the colon.
Figure 4. Immunohistochemical detection of DEFA5 protein in intestinal mucosa. No immunostaining can be seen in normal colon (A),
while Paneth cells and follicle centers in Peyer’s patches are immunoreactive in normal ileum (B). Mucosal defects with inflammatory cells staining for
DEFA5 in untreated UC (C) and Paneth cell loss with diminished DEFA5 staining in active CDi (D). Rare DEFA5-positive metaplastic Paneth cells in
colonic mucosa of UC responders after infliximab (E). No difference in DEFA5 immunoreactivity when comparing CDi responders with untreated CDi
(F). (OM (A): 6100; OM (B–F): 650).
doi:10.1371/journal.pone.0007984.g004
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Appendix S1 A glossary of terms used in the methods.
Found at: doi:10.1371/journal.pone.0007984.s001 (0.03 MB
DOC)
Figure S1 qPCR analysis of DEFB1 (A), LEAP2 (B), PYY (C),
DEFA5 (D), DEFA6 (E) and DEFB4 (F) in intestinal mucosa of
IBD patients before and after first infliximab treatment. A line
between 2 points represents the change in expression before and
after treatment for one patient. R: responders.
Found at: doi:10.1371/journal.pone.0007984.s002 (2.18 MB TIF)
Table S1 A list of the 81 AMP proteins that were investigated in
the present study.
Found at: doi:10.1371/journal.pone.0007984.s003 (0.03 MB
XLS)
Table S2 The microarray analysis results (FC, p-value and
FDR) for all the probe sets representing AMP genes of the
performed comparative analyses by LIMMA in and between UC,
CDc, IBDc and CDi. R: responders, NR: non-responders.
Found at: doi:10.1371/journal.pone.0007984.s004 (0.23 MB
XLS)
Table S3 The results (p-value) from the comparative analyses of
the qPCR data of DEFB1, LEAP2, PYY, DEFA5, DEFA6 and
DEFB4 in intestinal mucosa of IBD patients before and after first
infliximab treatment. R: responders, NR: non-responders.
Found at: doi:10.1371/journal.pone.0007984.s005 (0.02 MB
XLS)
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